RELAPSTAPH: Recurrent S. Aureus Infections in Osteoarticular Infections

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Recruiting
CT.gov ID
NCT04712123
Collaborator
(none)
40
1
17
2.4

Study Details

Study Description

Brief Summary

Staphylococcus aureus osteoarticular infections, in particular those associated with the presence of implant, relapse in 20% of cases. Currently, the reasons for these relapses are poorly understood, whether on the microbiological or clinical side.

The aim of this study is to improve knowledge on persistence of mechanisms of S. aureus

Condition or Disease Intervention/Treatment Phase
  • Other: relapse due to S. aureus

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Recurrent S. Aureus Infections in Osteoarticular Infections
Actual Study Start Date :
Aug 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
relapse due to S. aureus

patients having had an initial infection due to S. aureus and who present a relapse with persistence of S. aureus

Other: relapse due to S. aureus
to find out if it is the same S. aureus in both infections

Outcome Measures

Primary Outcome Measures

  1. rate of patients having had an osteoarticular infection due to S. aureus [between 2015 and 2020]

    proportion of patients having had an osteoarticular infection due to S. aureus

  2. Description of patients having had an osteoarticular infection due to S. aureus [between 2015 and 2020]

    type of patients: age, BMI, comorbidities...

  3. Description of Bone and Joint Iinfection/Prosthesis Joint Infection [between 2015 and 2020]

    implant or prosthesis or not, acute/ chronic, bacteriology

Secondary Outcome Measures

  1. rate of patients having had a relapse due to persistence of S. aureus [between 2015 and 2020]

    proportion of patients having had an osteoarticular infection due persistence of S. aureus

  2. rate of S. aureus strain identical between the initial episode and the relapse [between 2015 and 2020]

    proportion of relapse due to the same strain of S. aureus than in the initial episode

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients having had an osteoarticular infection with or without material due to S. aureus presenting a recurrence of S. aureus infection
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices Civils de Lyon Lyon France 69004

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT04712123
Other Study ID Numbers:
  • 281
First Posted:
Jan 15, 2021
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022